ERJ Open Research (Feb 2024)

Purine degradation pathway metabolites at birth and the risk of lower respiratory tract infections in infancy

  • Maria J. Gutierrez,
  • Gustavo Nino,
  • Sonia Restrepo-Gualteros,
  • Ethan Mondell,
  • Elizabeth Chorvinsky,
  • Surajit Bhattacharya,
  • Bethlehem Solomon Bera,
  • Allison Welham,
  • Xiumei Hong,
  • Xiaobin Wang

DOI
https://doi.org/10.1183/23120541.00693-2023
Journal volume & issue
Vol. 10, no. 1

Abstract

Read online

Background Lower respiratory tract infections (LRTIs) are the leading cause of infant morbidity and mortality worldwide, and altered metabolite production is recognised as a critical factor in LRTI pathogenesis. Methods This study aimed to identify prenatal metabolic changes associated with LRTI risk in infancy, using liquid chromatography-mass spectrometry unbiased metabolomics analysis on cord blood from 810 full-term newborns. Results We identified 22 compounds linked to LRTIs in infancy, enriched for purine degradation pathway (PDP) metabolites. High cord blood PDP metabolites, including xanthine, hypoxanthine, xanthosine and inosine, were linked to reduced LRTI risk during infancy. Notably, a low xanthine to uric acid ratio at birth predicted a four-fold increased LRTI risk. Conclusion This study is the first to reveal that high cord blood PDP metabolites identify newborns at lower LRTI risk, stratifying disease risk at birth. Moreover, our results prompt further study on PDP enzymes as pharmacological targets to decrease LRTI morbidity and mortality for at-risk newborns.